News
KZIA
--
0.00%
--
Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4
LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed glioblastoma multiforme (GBM) patients, as well...
ACCESSWIRE · 4d ago
Maxim Group Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $18
Maxim Group analyst Naureen Quibria initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $18.
Benzinga · 4d ago
What Kind Of Investors Own Most Of Kazia Therapeutics Limited (ASX:KZA)?
If you want to know who really controls Kazia Therapeutics Limited ( ASX:KZA ), then you'll have to look at the makeup...
Simply Wall St. · 5d ago
Kazia Therapeutics To Present At LD Micro Main Event From Oct. 12-14
Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)))), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be held
Benzinga · 10/06 14:01
Kazia Therapeutics to Present at LD Micro Main Event
Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr , will be presenting at the LD Micro Main Event, to be held virtually and in person from .
PR Newswire - PRF · 10/06 14:00
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from...
PR Newswire · 09/10 16:30
Investing in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 241% gain
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
Simply Wall St. · 09/07 22:36
Kazia Therapeutics Announced EVT801 Phase I Study Receives Full Regulatory Approval in France
Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to inform stakeholders that the planned phase I study for EVT801 has received full approval from L'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), the French regulatory agency...
Benzinga · 09/02 09:35
When Will Kazia Therapeutics Limited (ASX:KZA) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Kazia Therapeutics...
Simply Wall St. · 08/02 21:31
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and g...
PR Newswire - PRF · 07/21 14:00
BRIEF-Kazia Therapeutics Provides Progress Update On Paxalisib And Evt801 Clinical Programs
reuters.com · 06/30 14:36
Kazia provides progress update on paxalisib and EVT801 clinical programs
Kazia Therapeutics ([[KZIA]] +3.9%) provides an update on recent progress with its two pipeline assets, paxalisib and EVT801.The company's GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with
Seekingalpha · 06/30 14:14
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801.
PR Newswire - PRF · 06/30 14:00
Kazia Therapeutics Announced Manufacturing Patents Granted for Paxalisib in Key Territories; Extend Effective Patent Protection to 2036
Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to announce the grant of patents by the respective agencies of the United States and India in respect of the manufacturing process for paxalisib. A similar patent has been accepted in Australia and is ex...
Benzinga · 06/24 10:05
How Many Kazia Therapeutics Limited (ASX:KZA) Shares Did Insiders Buy, In The Last Year?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
Simply Wall St. · 06/16 19:36
Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial
Kazia Therapeutics ([[KZIA]] +1.5%) has entered a collaboration with Cornell University in the United States, to launch a phase II clinical study investigating the use of the company's paxalisib in combination
Seekingalpha · 06/15 14:25
BRIEF-Kazia Enters Clinical Collaboration With Cornell University
reuters.com · 06/15 14:23
Kazia Pursues Collaboration in Phase 2 Study of Paxalisib-Ketogenesis Combination For Glioblastoma
MT Newswires · 06/15 11:11
Kazia Therapeutics on Monday, Announced Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United States, to launch a phase II clinical study investigating the use of Ka...
Benzinga · 06/15 09:29
Webull provides a variety of real-time KZIA stock news. You can receive the latest news about Kazia through multiple platforms. This information may help you make smarter investment decisions.
About KZIA
Kazia Therapeutics Limited is an Australia-based oncology-focused drug development company. The Company collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The Company entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The Company entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.